- Corporate Officers - S
- Szela Mary T
Insider Trading History of Szela Mary T
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Szela Mary T since 2007.
This trader's CIK number is 1410289.
At the time of last reporting, Szela Mary T was the CEO AND PRESIDENT of Trisalus Life Sciences, Inc.. (stock ticker symbol TLSI).
Also see all insider trading activities at Trisalus Life Sciences, Inc..
Note that in the past
Szela Mary T also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Coherus Biosciences, Inc. (CHRS) by Szela Mary T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2020 | CHRS | 0 | $0 | 54,997 | $966,737 | 54,997 | $456,860 |
Yearly summary of insider trading at Trisalus Life Sciences, Inc. (TLSI) by Szela Mary T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | TLSI | 19,582 | $102,053 | 0 | $0 | 0 | $0 |
| 2024 | TLSI | 19,815 | $99,808 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Novelion Therapeutics Inc. (NVLN) by Szela Mary T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | NVLN | 0 | $0 | 0 | $0 | 6,632 | $0 |
Yearly summary of insider trading at Abbott Laboratories (ABT) by Szela Mary T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2011 | ABT | 0 | $0 | 88,416 | $4,606,424 | 69,161 | $3,620,946 |
| 2010 | ABT | 0 | $0 | 25,031 | $1,361,472 | 447 | $23,177 |
| 2009 | ABT | 0 | $0 | 10,629 | $477,315 | 5,535 | $270,264 |
| 2008 | ABT | 0 | $0 | 3,494 | $187,090 | 43,400 | $1,854,649 |
| 2007 | ABT | 0 | $0 | 8,327 | $437,167 | 0 | $0 |
Insider trading activities at 4 companies by Szela Mary T:
1. Coherus Biosciences, Inc. (CHRS)
2. Trisalus Life Sciences, Inc. (TLSI)
3. Novelion Therapeutics Inc. (NVLN)
4. Abbott Laboratories (ABT)
Table 1. Insider trading of Coherus Biosciences, Inc. (CHRS) by Szela Mary T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2020-06-22 | CHRS | Option Ex | 54,997 | 8.31 | 456,860 |
| 2020-06-22 | CHRS | Sale | 54,997 | 17.58 | 966,737 |
Table 2. Insider trading of Trisalus Life Sciences, Inc. (TLSI) by Szela Mary T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-01-29 | TLSI | Buy | 5,030 | 5.03 | 25,300 |
| 2025-01-30 | TLSI | Buy | 5,010 | 5.28 | 26,452 |
| 2025-01-27 | TLSI | Buy | 4,826 | 5.42 | 26,156 |
| 2025-01-28 | TLSI | Buy | 4,716 | 5.12 | 24,145 |
| 2024-09-13 | TLSI | Buy | 7,295 | 4.92 | 35,854 |
| 2024-09-12 | TLSI | Buy | 7,520 | 5.20 | 39,104 |
| 2024-09-10 | TLSI | Buy | 5,000 | 4.97 | 24,850 |
Table 3. Insider trading of Novelion Therapeutics Inc. (NVLN) by Szela Mary T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-05-09 | NVLN | Option Ex | 6,632 | .00 | 0 |
Table 4. Insider trading of Abbott Laboratories (ABT) by Szela Mary T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2011-12-14 | ABT | Option Ex | 53,201 | 53.62 | 2,852,903 |
| 2011-12-14 | ABT | Sale | 53,201 | 54.38 | 2,893,229 |
| 2011-03-31 | ABT | Option Ex | 15,960 | 48.12 | 768,043 |
| 2011-03-31 | ABT | Sale | 15,960 | 49.26 | 786,109 |
| 2011-02-28 | ABT | Sale | 1,988 | 48.30 | 96,026 |
| 2011-03-01 | ABT | Sale | 17,267 | 48.13 | 831,060 |
| 2010-03-01 | ABT | Sale | 23,084 | 54.44 | 1,256,785 |
| 2010-02-16 | ABT | Sale | 1,500 | 53.93 | 80,898 |
| 2010-02-10 | ABT | Option Ex | 447 | 51.85 | 23,177 |
| 2010-02-10 | ABT | Sale | 447 | 53.22 | 23,789 |
| 2009-05-01 | ABT | Sale | 8,122 | 41.56 | 337,590 |
| 2009-02-17 | ABT | Sale | 417 | 54.40 | 22,685 |
| 2009-02-04 | ABT | Option Ex | 3,445 | 45.45 | 156,568 |
| 2009-02-03 | ABT | Sale | 2,090 | 56.00 | 117,040 |
| 2009-02-03 | ABT | Option Ex | 2,090 | 54.40 | 113,696 |
| 2008-09-08 | ABT | Option Ex | 2,474 | 45.45 | 112,438 |
| 2008-08-26 | ABT | Option Ex | 5,480 | 39.70 | 217,539 |
| 2008-07-09 | ABT | Option Ex | 12,376 | 45.45 | 562,464 |
| 2008-06-30 | ABT | Sale | 2,569 | 52.91 | 135,925 |
| 2008-05-14 | ABT | Option Ex | 3,834 | 42.75 | 163,895 |
| 2008-05-06 | ABT | Option Ex | 19,236 | 41.50 | 798,313 |
| 2008-02-29 | ABT | Sale | 334 | 53.99 | 18,031 |
| 2008-02-19 | ABT | Sale | 591 | 56.06 | 33,134 |
| 2007-09-12 | ABT | Sale | 8,327 | 52.50 | 437,167 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Szela Mary T
(CEO AND PRESIDENT of Trisalus Life Sciences, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.